The three main questions asked by governments and payers are “Can it work?”, “Will it work?” and “Is it worth it?”1. In order to answer these questions, real world data is essential. (Cost-)effectiveness should no longer be evaluated under ideal conditions in an ideal population, but in real world populations under real world conditions. With our rich data from multiple data sources we will be able to answer these questions for you. One of the advantages of our independent position is that we can give answers to the effects of a particular drug in relation to competitor drugs in the same class in a real world setting. Please contact us for more information.


1. Berger M, Mamdani M, Atkins D, Johnson ML. Good research practices for defining, reporting and interpreting non-randomized studies of treatment effects using secondary databases: Report of the ISPOR Retrospective Database Analysis Task Force – Part I